Why the study?
Cirrhotic cardiomyopathy is a risk factor for cardiovascular disease after liver transplantation, prompting assessment of whether the original 2005 or revised 2020 criteria better predict posttransplant major adverse cardiac events.
Does the revised 2020 criteria for cirrhotic cardiomyopathy predict major adverse cardiac events after liver transplantation better than the original 2005 criteria?
Population
210 adult LT recipients
Comparison
Original 2005 vs revised 2020 CCM criteria
Design
Single-center retrospective study
Authors
Loading...
Should not yet change pre-LT CCM screening; supports 2020 over 2005 criteria but leaves open prospective validation.
Does the revised 2020 criteria for cirrhotic cardiomyopathy predict major adverse cardiac events after liver transplantation better than the original 2005 criteria?
The revised 2020 criteria for cirrhotic cardiomyopathy, specifically abnormal septal e', successfully predict major adverse cardiac events after liver transplantation, validating the updated definition.
Spann et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: